Division of Gastroenterology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
PLoS One. 2022 Jun 2;17(6):e0269070. doi: 10.1371/journal.pone.0269070. eCollection 2022.
The aim of this study was to assess the risk of liver fibrosis in those with no glucose intolerance, prediabetes, or diabetes. A cross-sectional study was conducted based on a cohort from a health examination program which included a magnetic resonance elastography (MRE). Participants were classified into three groups according to glucose tolerance: no glucose intolerance, prediabetes, and diabetes mellitus. Liver fibrosis was evaluated by liver stiffness measurement (LSM) value using two-dimensional real-time MRE. The risk of significant liver fibrosis was compared among three groups. A total of 2,090 subjects were included: no glucose intolerance (n = 889); prediabetes (n = 985); and diabetes (n = 216). Mean values of LSM in those with no glucose intolerance, prediabetes, and diabetes were 2.37 ± 0.43 kPa, 2.41 ± 0.34 kPa, and 2.65 ± 0.70 kPa, respectively (p<0.001). Proportions of significant fibrosis (LSM ≥2.97 kPa) in no glucose intolerance, prediabetes, and diabetes groups were 3.1%, 4.4%, and 16.7%, respectively (p<0.001). Compared with those with no glucose intolerance, those with diabetes had higher risk of significant fibrosis (adjusted odds ratio [aOR]: 3.02, 95% confidence interval [CI]: 1.57-5.81, p<0.001). However, there was no difference between prediabetes and no glucose intolerance (aOR: 1.05, 95% CI: 0.59-1.86, p = 0.876). A subgroup analysis also showed that prediabetes, unlike diabetes, was not associated with significant fibrosis in subjects with or without liver disease. Diabetes, but not prediabetes, is a risk factor for significant liver fibrosis. This finding is consistent regarldess of the pressence of liver disease.
本研究旨在评估无葡萄糖耐量异常、糖尿病前期和糖尿病患者发生肝纤维化的风险。基于健康体检计划的队列进行了一项横断面研究,该计划包括磁共振弹性成像(MRE)。根据葡萄糖耐量将参与者分为三组:无葡萄糖耐量异常、糖尿病前期和糖尿病。使用二维实时 MRE 测量肝硬度值(LSM)评估肝纤维化。比较三组间发生显著肝纤维化的风险。共纳入 2090 例受试者:无葡萄糖耐量异常(n = 889);糖尿病前期(n = 985);糖尿病(n = 216)。无葡萄糖耐量异常、糖尿病前期和糖尿病患者的 LSM 平均值分别为 2.37 ± 0.43 kPa、2.41 ± 0.34 kPa 和 2.65 ± 0.70 kPa(p<0.001)。无葡萄糖耐量异常、糖尿病前期和糖尿病组中显著纤维化(LSM≥2.97 kPa)的比例分别为 3.1%、4.4%和 16.7%(p<0.001)。与无葡萄糖耐量异常者相比,糖尿病患者发生显著纤维化的风险更高(校正优势比[aOR]:3.02,95%置信区间[CI]:1.57-5.81,p<0.001)。然而,糖尿病前期与无葡萄糖耐量异常者之间无差异(aOR:1.05,95% CI:0.59-1.86,p = 0.876)。亚组分析还表明,与糖尿病不同,糖尿病前期与无或有肝病患者的显著纤维化无关。糖尿病,而不是糖尿病前期,是显著肝纤维化的危险因素。这一发现与是否存在肝病无关。